Dr Howard Zwibel discusses highlights of data presented at the 60th Annual Meeting of the AAN on comorbidities and quality of life in patients with multiple sclerosis. Medscape Neurology & Neurosurgery
A large study shows that older adults with dementia who start receiving antipsychotic drug therapy have an increased risk for hospitalization or death within 30 days. Medscape Medical News
In a trial of nondepressed patients with recent stoke, those who received escitalopram or problem-solving therapy were less likely to develop depression. Medscape Medical News
A recent Phase II study has demonstrated that oral FTY720 is effective in reducing disease activity in relapsing multiple sclerosis with a favorable adverse-effect profile. These results are awaiting confirmation in the three ongoing Phase III clinical trials Expert Review of Neurotherapeutics
Bulbar symptoms such as dysphagia and dysarthria are frequent features of amyotrophic lateral sclerosis and can result in reductions in life expectancy and quality of life. Nature Clinical Practice Neurology
